Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

The Utilisation of Dopaminergic Drugs in Croatia 2000 to 2010 (CROSBI ID 580804)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Sović Brkičić, Ljiljana ; Vončina, Luka ; Godman, Brian ; Sović, Slavica ; Relja, Maja ; The Utilisation of Dopaminergic Drugs in Croatia 2000 to 2010 // Program and Abstract Book 2011:15. EuroDURG/ISPE, Antwerpen, Belgium, 30 November – 3 December, 2011. / Godman, Brian (ur.). Antverpen, 2012

Podaci o odgovornosti

Sović Brkičić, Ljiljana ; Vončina, Luka ; Godman, Brian ; Sović, Slavica ; Relja, Maja ;

engleski

The Utilisation of Dopaminergic Drugs in Croatia 2000 to 2010

Introduction: Several studies have shown that levodopa is the most commonly used drug to treat patients with Parkinson's disease (PD), followed by dopamine agonists, MAO-B inhibitors and COMT inhibitors. However, the utilisation of levodopa continues to increase despite appreciable increases in the utilisation of newer dopamine agonists and COMT inhibitors. Objectives: Analyse utilisation of drugs to treat PD in Croatia 2000-2010 alongside reimbursed expenditure. In addition, assess the potential rationale for any changes in utilisation and expenditure patterns to guide future activities. Methodology: Retrospective analysis of the utilisation of drugs in ambulatory care to treat PD (N04BA, N04BB, N04BC and N04BD) in DDDs and DDDs/ TID (2011 DDDs) using Croatian Institute for Health Insurance (HZZO) databse from 2000-2010. Biperiden (N04AA) is not typically prescribed in PD ; consequently, not included in the study. Only reimbursed costs included as the analysis is from the Health Insurance perspective, and measured in Croatian kuna (HRK). Details of the reforms and initiatives documented with the help of the co-authors. Results: Drug utilisation increased by 218% from 0.78 DDDs/TID in 2000 to 2.48 in 2010. Levodopa increased from 0.59 to 1.09, dopamine agonists from 0.05 to 0.88, and MAO-Bs from 0.15 to 0.44, whilst utilisation of COMT inhibitors remained stable after 2005 at 0.07 DDDs/ TID. Increased utilisation of dopamine agonists and MAO-Bs including rasagiline increased reimbursed expenditure by 366% during the study period. Conclusion: The consumption of PD drugs increased in Croatia during the study period in line with expectations, with again increased utilisation of levodopa alongside newer drugs. Further analysis is currently taking place regarding the rationale behind greater increases in expenditure than utilization, with a view to implementing possible additional measures as resource pressures grow.

dopaminergic drug; utilisation ;

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

2012.

objavljeno

Podaci o matičnoj publikaciji

Program and Abstract Book 2011:15. EuroDURG/ISPE, Antwerpen, Belgium, 30 November – 3 December, 2011.

Godman, Brian

Antverpen:

Podaci o skupu

Nepoznat skup

poster

29.02.1904-29.02.2096

Povezanost rada

Javno zdravstvo i zdravstvena zaštita